http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20120828:nBw276140a
   SOLNA, Sweden & ANTONY, France--(Business Wire)--Aerocrine AB (STO:AERO.B) and Stallergenes S.A (Euronext Paris CAC small) todayannounce the signing of an exclusive multi-year distribution agreement forAerocrine`s airway inflammation monitor and test Kit. The agreement willinitially cover France, Italy, Poland, Turkey and the Middle East and could beextended to additional countries. The agreement, which comes into effect on 1 September 2012, gives Stallergenesexclusive rights for the marketing, sales and distribution of Aerocrine`sinstrument NIOX MINO and test kits, used for diagnosing and monitoring patientswith asthma. The existing distribution agreement of Aerocrine withThermoFisher/Phadia which covers France and Italy will be terminated on theeffective date of this new agreement. Aerocrine offers versatile and easy-to-use exhaled Nitric Oxide (NO) monitoringdevices for research and clinical applications. Aerocrine`s compact hand-helddevice is intended for routine measurements, where it can be used to improve themanagement of asthma and other inflammatory airway conditions in both specialistand primary care clinics. NIOX MINO offers added advantages for patient careincluding detecting of eosinophilic airway inflammation, determining thelikelihood of corticosteroid responsiveness, monitoring of airway inflammationto determine the potential need for corticosteroid, and unmasking of otherwiseunsuspected non adherence to corticosteroid therapy 
  1
  (
  http://connect.ne.cision.com#_ftn1
 ). The agreement will initially cover France, Italy, Poland, Turkey and the MiddleEast and could be extended to additional countries. Aerocrine`s products arealready approved for commercialisation. Stallergenes will provide adequateresources to market the products, depending on a country basis scenario. "Stallergenes has a strong product portfolio and well-established local salesforces with a good network of relationships in the clinical world", says ScottMyers, CEO of Aerocrine. With Stallergenes as distributor, Aerocrine gains access to one of the largerproviders of both diagnostic and therapeutic products and will benefit fromStallergenes excellent network in the specialist segment. Scott Myers continues, "We believe Stallergenes is a good partner for us. Theyknow the market well and have the resources that we need and could not fund atthis time. The terms of the agreement offer financial benefits to both companiesonce executed". "We are delighted to team up with Aerocrine, the established leader in themeasurement and monitoring of airway inflammation. This partnership willreinforce our expertise and offer allergologists and pulmonologists an importanttool for a tailored treatment of asthmatic patients. This project not onlyenables us to enlarge our product offering, specifically designed for allergicand asthmatic patients, but is also perfectly in line with Stallergenes`strategy in asthma development", says Roberto Gradnik, Chief Executive Officerof Stallergenes. The terms of the agreement are undisclosed. ABOUT ASTHMA Asthma is a chronic inflammatory disease of the airways characterised bysymptoms including coughing, wheezing and difficulty in breathing. Asthma is oneof this world`s most common and costly diseases, affecting 8-10% of the worldpopulation, and is always in the top five in terms of costs relating to chronicdiseases. The prevalence of asthma has been gradually increasing over the last20 years in industrialised countries, at a rate of around 5% per year. Asthma isvery often linked to allergic rhinitis: 80% of allergic asthma sufferers alsohave allergic rhinitis and 40% of patients with untreated rhinitis go on todevelop asthma. Inadequate control of asthma is common and leads to a poorer quality of life andincorrect dosage of medication. Aerocrine`s instrument NIOX MINO plays asignificant role and is key to effective asthma management. About Aerocrine Aerocrine AB is a medical technology company focused on the improved managementand care of patients with inflammatory airway diseases. As the pioneer andleader in technology to monitor and manage airway inflammation, Aerocrinemarkets NIOX MINO and NIOX Flex. Both products enable fast and reliablemanagement of airway inflammation and may therefore play a critical role in moreeffective diagnosis, treatment and follow-up of patients with inflammatoryairway diseases such as asthma. Aerocrine is based in Sweden with subsidiariesin the U.S., Germany, and the U.K. Aerocrine shares were listed on the StockholmStock Exchange in 2007. ABOUT STALLERGENES Stallergenes is a European biopharmaceutical company dedicated to the treatmentof allergy-related respiratory diseases, such as severe rhinoconjunctivitis andrhinitis, as well as allergic asthma, using allergen immunotherapy. The seventhlargest pharmaceutical company in France and the leader in sublingualimmunotherapy treatment, Stallergenes devotes almost 20% of its gross turnoverto Research & Development and is actively involved in the development of a newtherapeutic class, sublingual immunotherapy tablets. In 2011, the company had a turnover of 235 million Euros, and more than 500,000patients were treated with Stallergenes products. Euronext Paris (Compartiment B)CAC smallCode ISIN : FR0000065674Code Reuters :GEN.PA Code Bloomberg : GEN.FP Additional information is available at 
  www.stallergenes.com
 Forward-looking statements related to Stallergenes This press release may contain forward-looking statements, including forecastsof future revenue and operating profit as well as expected business-relatedevents. Such statements are based upon the current beliefs and expectations ofStallergenes` management and are subject to risks and uncertainties. Actualresults may differ from those set forth in the forward-looking statements, dueto various factors. Without being exhaustive, such factors include economicsituations and business conditions, including legal and product evaluationissues, fluctuations in currencies and demand, changes in competitive factorsand reliance on suppliers. The Company disclaims any intention or obligation toupdate or revise any forward-looking statements whether as a result of newinformation or future events and except as required by law. Aerocrine may be required to disclose the information provided herein pursuantto the Securities Markets Act and/or the Financial Instruments Trading Act. Theinformation was submitted for publication at 8:00 a.m. on August 28, 2012.  
  1
   An Official ATS Clinical Practice Guideline: Interpretation of ExhaledNitric Oxide Levels (FeNO) for Clinical Applications Am. J. Respir. Crit. Care Med. 2011 184: 602-615 This information was brought to you by Cision 
  http://www.cisionwire.com
   StallergenesRoberto Gradnik, Chief Executive OfficerTel. +33 1 55 59 20 04orInvestor and Analyst RelationsChristian Thiry, Chief Financial OfficerTel. +33 1 55 59 20 95e-mail: investorrelations@stallergenes.frorPavie Finance: Lucile de FraguierTel. +44 208 248 2793e-mail: contact@pavie-finance.comorPress RelationsLise Lemonnier, Senior Communication DirectorTel. + 33 1 55 59 20 96e-mail: llemonnier@stallergenes.frorChandler Chicco Agency: Bahar TurkogluTel.: + 33 1 41 43 02 27e-mail: bturkoglu@ccapr.comorAerocrineScott Myers, President & CEO, Aerocrine ABPhone: +46 768 788 379 Copyright Business Wire 2012